Back to Browse Journals » International Journal of Nanomedicine » Volume 8 » Issue 1

Nanodiscs as a therapeutic delivery agent: inhibition of respiratory syncytial virus infection in the lung

Authors Numata M, Grinkova YV, Mitchell JR, Chu HW, Sligar SG, Voelker DR

Received 3 November 2012

Accepted for publication 22 December 2012

Published 15 April 2013 Volume 2013:8(1) Pages 1417—1427

DOI https://dx.doi.org/10.2147/IJN.S39888

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Mari Numata,1 Yelena V Grinkova,2 James R Mitchell,1 Hong Wei Chu,1 Stephen G Sligar,2 Dennis R Voelker1

1Department of Medicine, Program in Cell Biology, National Jewish Health, Denver, CO, USA; 2Department of Biochemistry, University of Illinois, Urbana, IL, USA

Abstract: There is increasing interest in the application of nanotechnology to solve the difficult problem of therapeutic administration of pharmaceuticals. Nanodiscs, composed of a stable discoidal lipid bilayer encircled by an amphipathic membrane scaffold protein that is an engineered variant of the human Apo A-I constituent of high-density lipoproteins, have been a successful platform for providing a controlled lipid composition in particles that are especially useful for investigating membrane protein structure and function. In this communication, we demonstrate that nanodiscs are effective in suppressing respiratory syncytial viral (RSV) infection both in vitro and in vivo when self-assembled with the minor pulmonary surfactant phospholipid palmitoyloleoylphosphatidylglycerol (POPG). Preparations of nanodiscs containing POPG (nPOPG) antagonized interleukin-8 production from Beas2B epithelial cells challenged by RSV infection, with an IC50 of 19.3 µg/mL. In quantitative in vitro plaque assays, nPOPG reduced RSV infection by 93%. In vivo, nPOPG suppressed inflammatory cell infiltration into the lung, as well as IFN-γ production in response to RSV challenge. nPOPG also completely suppressed the histopathological changes in lung tissue elicited by RSV and reduced the amount of virus recovered from lung tissue by 96%. The turnover rate of nPOPG was estimated to have a half-time of 60–120 minutes (m), based upon quantification of the recovery of the human Apo A-I constituent. From these data, we conclude that nPOPG is a potent antagonist of RSV infection and its inflammatory sequelae both in vitro and in vivo.

Keywords: nanodiscs, therapeutic delivery, anti-viral, innate immunity, phospholipids

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Diagnostic and therapeutic utility of neuroimaging in depression: an overview

Wise T, Cleare AJ, Herane A, Young AH, Arnone D

Neuropsychiatric Disease and Treatment 2014, 10:1509-1522

Published Date: 19 August 2014

Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles

Rangger C, Helbok A, Sosabowski J, Kremser C, Koehler G, Prassl R, Andreae F, Virgolini IJ, von Guggenberg E, Decristoforo C

International Journal of Nanomedicine 2013, 8:4659-4671

Published Date: 5 December 2013

Silymarin-loaded solid nanoparticles provide excellent hepatic protection: physicochemical characterization and in vivo evaluation

Yang KY, Hwang DH, Yousaf AM, Kim DW, Shin YJ, Bae ON, Kim YI, Kim JO, Yong CS, Choi HG

International Journal of Nanomedicine 2013, 8:3333-3343

Published Date: 28 August 2013

Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells

Kim DH, Jeong YI, Chung CW, Kim CH, Kwak TW, Lee HM, Kang DH

International Journal of Nanomedicine 2013, 8:1697-1711

Published Date: 30 April 2013

Paclitaxel-Fe3O4 nanoparticles inhibit growth of CD138–  CD34– tumor stem-like cells in multiple myeloma-bearing mice

Yang C, Wang J, Chen D, Chen J, Xiong F, Zhang H, Zhang Y, Gu N, Dou J

International Journal of Nanomedicine 2013, 8:1439-1449

Published Date: 12 April 2013

Application of liposomes in drug development – focus on gastroenterological targets

Zhang JX, Wang K, Mao ZF, Fan X, Jiang DL, Chen M, Cui L, Sun K, Dang SC

International Journal of Nanomedicine 2013, 8:1325-1334

Published Date: 8 April 2013